HOME INVESTORS Investors We communicate with our investors through online updates, press releases, webinars, financial results, the publication of the Annual Report and annual meetings of shareholders. Cookies: This website uses cookies Check the cookies page for more information ACCEPT DECLINE

HOME ABOUT US CORPORATE GOVERNANCE Corporate governance Pharming recognizes the importance of clear and transparent regulations in respect of corporate governance for the confidence of investors in its policies and strategy. Cookies: This website uses cookies Check the cookies page for more information ACCEPT DECLINE

HOME ABOUT US BOARD OF DIRECTORS Board of Directors Sijmen de Vries, MD MBA Sijmen de Vries, MD MBA Executive Director and Chief Executive Officer Dr. de Vries has been our Chief Executive Officer since 2008, and he has also served in the capacity of interim Chief Financial Officer from May 2020 through November 16, 2020, upon the commencement of Mr. Wakkerman’s tenure as Chief Financial Officer. Dr. de Vries is responsible for daily management of the company and the execution of the strategy. Prior to joining Pharming, Dr. de Vries was the CEO of 4-Antibody and Morphochem AG. Dr. de Vries also held senior business and commercial positions at Novartis, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals plc. Dr. de Vries holds an MD degree from the University of Amsterdam and an MBA in General Management from Ashridge Management College in the United Kingdom. Dr. de Vries is on the Board of Directors of Pharming's fill & finish partner, BioConnection B.V. and is also a non-executive director of Midatech Pharma plc. Cookies: This website uses cookies Check the cookies page for more information ACCEPT DECLINE

HOME PRIVACY STATEMENT Privacy Statement At Pharming Group N.V. (“we” “us” “Pharming”) we are committed to protecting your personal data. If you use our website, we may collect information that can be used to identify you (“personal data”). Cookies: This website uses cookies Check the cookies page for more information ACCEPT DECLINE

HOME PIPELINE PRE-ECLAMPSIA Pre-eclampsia We are developing a rhC1INH protein replacement therapy for the treatment of pre-eclampsia. Cookies: This website uses cookies Check the cookies page for more information ACCEPT DECLINE